# GLYXAMBI
> **NDA206073** · New Drug Application · Sponsor: BOEHRINGER INGELHEIM · Approved 2015-01-30
## Drug
- **FDA Application Number:** NDA206073
- **Application type:** New Drug Application
- **Brand name:** GLYXAMBI
- **Generic name:** EMPAGLIFLOZIN AND LINAGLIPTIN
- **Active ingredients:** EMPAGLIFLOZIN; LINAGLIPTIN
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** Prescription
- **Sponsor:** BOEHRINGER INGELHEIM
- **Manufacturer:** Boehringer Ingelheim Pharmaceuticals, Inc.
- **First approval:** 2015-01-30
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206073)
---
*AI Analytics · CC0 1.0*